. 2014 Mar 14;10(5):1366–1372. doi: 10.4161/hv.28397

Table 3. The GMT ratios among different batches of EV71 vaccine in subjects who were seronegative at baseline on day 56, by treatment and age groups.

Batch number	n	GMT (95% CI)	GMT ratio (95% CI)
6–11 mo
Batch 1	343	420.1 (359.8–490.5)	1.02 (0.82–1.27)
Batch 2	330	413.1 (353.7–482.4)	1.02 (0.82–1.27)
Batch 1	343	420.1 (359.8–490.5)	0.89 (0.69–1.06)
Batch 3	325	489.6 (422.3–567.6)	0.89 (0.69–1.06)
Batch 2	330	413.1 (353.7–482.4)	0.84 (0.68–1.05)
Batch 3	325	489.6 (422.3–567.6)	0.84 (0.68–1.05)
12–35 mo
Batch 1	796	401.5 (362.0–445.4)	0.82 (0.71–0.94)
Batch 2	823	492.2 (448.6–540.1)	0.82 (0.71–0.94)
Batch 1	796	401.5 (362.0–445.4)	0.75 (0.66–0.87)
Batch 3	813	533.6 (486.0–585.8)	0.75 (0.66–0.87)
Batch 2	823	492.2 (448.6–540.1)	0.92 (0.81–1.05)
Batch 3	813	533.6 (486.0–585.8)	0.92 (0.81–1.05)
Total
Batch 1	1139	407.0 (373.5–443.6)	0.87 (0.77–0.98)
Batch 2	1153	468.1 (432.2–507.0)	0.87 (0.77–0.98)
Batch 1	1139	407.0 (373.5–443.6)	0.78 (0.70–0.88)
Batch 3	1138	520.6 (481.2–563.3)	0.78 (0.70–0.88)
Batch 2	1153	468.1 (432.2–507.0)	0.90 (0.80–0.99)
Batch 3	1138	520.6 (481.2–563.3)	0.90 (0.80–0.99)

n, number of subjects. The equivalence margin of GMT is 0.67–1.5. The results were calculated on basis of subjects whom completed the two-dose immune schedule and had their serum detection results at day 56.